Aradigm's team represents a rare combination of multidisciplinary expertise and has experience bringing a variety of pharmaceutical and health care products to market in the U.S. and internationally. Members of the company's Scientific Advisory Board are among the world's leading experts in pulmonary medicine. Together, this leadership team is pioneering important advancements in the pulmonary pharmaceutical industry and positioning Aradigm as a new leader in the specialty pharmaceutical market.

Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

Ms. Pecota has more than 20 years of experience in corporate accounting and operations management. She previously served as Chief Financial Officer for NuGEN Technologies, Inc., a life sciences tools company that provides specialty reagents to pharmaceutical and diagnostics companies. Prior to that she served as a financial consultant to early- and mid-stage life sciences companies, developing fundable business models and assessing and improving internal financial preparation and reporting processes. She has served as Vice President, Finance and Administration at Signature BioScience, Inc., a venture-backed biopharmaceutical company; and as Director, Finance and Accounting for ACLARA BioSciences, Inc., a biotechnology company. Ms. Pecota holds a Bachelor of Science in Economics from San Jose State University and was among the executives named in the San Francisco Business Times "100 Most Influential Bay Area Business Women" in 2002 and 2003.

Mr. Grimes has served as our General Counsel & Corporate Secretary since June 2007. From May 2005 to June 2007, Mr. Grimes was an attorney in the Trademark & Brands department at Intel Corporation's headquarters in Santa Clara, CA. From May 2002 to January 2005, Mr. Grimes was Assistant General Counsel at Connetics Corporation, a publicly-traded specialty pharmaceutical company focused on dermatology, located in Palo Alto, CA. From February 2000 to April 2002, Mr. Grimes was Vice President, Corporate Counsel & Secretary of GN ReSound, Inc. and Beltone Electronics Corporation, both subsidiaries of a Danish-based multinational leading medical device company for hearing devices, reporting at various times during his tenure in Copenhagen, Denmark; Redwood City, CA; and Chicago, IL. Prior to becoming in-house counsel, Mr. Grimes was a commercial litigator for seven years. Mr. Grimes holds J.D./M.B.A. degrees and a B.S. in Finance from University of Colorado, Boulder. Mr. Grimes is a member of the Biotechnology Industry Organization – General Counsel Committee.